Navigation Links
Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filings in Europe
Date:6/3/2009

OSAKA, Japan, June 3 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") announced today that it has reviewed the development strategy for the Marketing Authorization Applications (MAAs) for its investigational compounds, alogliptin and alogliptin/ACTOS (generic name: pioglitazone HCl), in Europe, and accordingly, has initiated an additional long-term clinical study for alogliptin.

The additional two-year study is to evaluate the efficacy and safety of alogliptin compared to glipizide when used in combination with metformin in targeted number of almost 2,500 subjects with type 2 diabetes, whose blood sugar level is inadequately controlled with metformin.

With the results of this additional study, Takeda expects that the MAA submissions will be made with a more robust data set necessary to ensure its approval, and as a result, the target timing of MAAs is revised from the original plan of mid-2009 to 2012.

Alogliptin, which was discovered by Takeda's wholly owned U.S. subsidiary, Takeda San Diego, Inc. is a dipeptidyl peptidase IV (DPP-4) inhibitor for the treatment of type 2 diabetes. By providing complementary mechanisms of action, alogliptin/ACTOS targets the core defects of type 2 diabetes - insulin resistance (when the body does not efficiently use the insulin it produces) and insulin deficiency (when the body does not produce enough insulin).

Takeda Pharmaceutical Company Limited

Located in Osaka, Japan, Takeda (TSE:4502) is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products.


'/>"/>
SOURCE Takeda Pharmaceutical Company Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
2. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
3. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
4. Takedas Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed
5. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
6. Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
7. Revised: Challenging the Norm May Lead to New Therapy for Type 2 Diabetes
8. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
9. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
10. Fralex provides update on timing of interim analysis results
11. Phase 3 Results for Alogliptin Demonstrated Significant Blood Sugar Reductions in Monotherapy and Four Add-on Therapy Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... 15, 2014 /PRNewswire/ -  Pivotal Therapeutics Inc. (OTCQX:PVTTF; ... company with a focus on Omega-3 therapies for ... the Board of Directors approved the granting of ... the close of business on Friday, September 12, ... common shares of the Company were granted in ...
(Date:9/15/2014)... 15, 2014 /PRNewswire-iReach/ -- "Spain Aesthetic Lasers and ... market data on the Spain Aesthetic Lasers and ... millions of US dollars, volume (in units) and ... Invasive Body Contouring Devices (Laser-Assisted Liposuction (LAL) Devices ... Devices, Ultrasound-Assisted Liposuction (UAL) Devices and Power Assisted ...
(Date:9/15/2014)... /PRNewswire-iReach/ -- On September 8, 2014, Dr. ... a Citizen Petition to Dr. Margaret Hamburg ... another Black Box Warning to Levaquin, Cipro, and ... a Black Box Warning for the following psychiatric ... or acts, loss of consciousness, delirium, depressed level ...
Breaking Medicine Technology:Pivotal Therapeutics Grants Incentive Stock Options 2Spain Aesthetic Lasers and Energy Devices Market (LAL, RFAL, PAL, HIFU) Outlook to 2020 2Spain Aesthetic Lasers and Energy Devices Market (LAL, RFAL, PAL, HIFU) Outlook to 2020 3Spain Aesthetic Lasers and Energy Devices Market (LAL, RFAL, PAL, HIFU) Outlook to 2020 4Spain Aesthetic Lasers and Energy Devices Market (LAL, RFAL, PAL, HIFU) Outlook to 2020 5Quinolone Vigilance Foundation Supports Citizen Petition Requesting Another Black Box Warning for Levaquin, Cipro, Avelox 2Quinolone Vigilance Foundation Supports Citizen Petition Requesting Another Black Box Warning for Levaquin, Cipro, Avelox 3
... Reportlinker.com announces that a new ... its catalogue: Epidemiology: ... risk factor for deep vein thrombosis ... http://www.reportlinker.com/p0536561/Epidemiology-Major-Abdominal-Surgery-–-A-key-risk-factor-for-deep-vein-thrombosis-and-pulmonary-embolism.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=NoCategory ...
... 2011 Zimmer Holdings, Inc. (NYSE and SIX: ZMH), ... will be participating in the Goldman Sachs 32nd Annual ... Palos Verdes, California, on June 7, 2011, at 8:40 ... of the presentation can be accessed via Zimmer,s Investor ...
Cached Medicine Technology:Reportlinker Adds Epidemiology: Major Abdominal Surgery - A key risk factor for deep vein thrombosis and pulmonary embolism 2Zimmer Holdings to Present at the Goldman Sachs 32nd Annual Global Healthcare Conference 2
(Date:9/15/2014)... Alto, CA (PRWEB) September 15, 2014 ... anniversary since its founding in 2007. To mark the ... local community for supporting the village and helping it ... provides a safe, secure and fun community for seniors. ... to the community and live in their own homes. ...
(Date:9/15/2014)... Dennis Thompson ... News) -- The severe respiratory virus believed to have ... states has now spread to the Northeast, health officials ... confirmed on Friday more than a dozen cases of ... for children with asthma. And on Saturday, the ...
(Date:9/15/2014)... neuroscience research has shown that certain brain regions ... language, naming, and decision-making. , How and where ... to support complex cognition is still under investigation. ... Washington University in St. Louis, Missouri, believe that ... the brain to function as an integrated network. ...
(Date:9/15/2014)... 2014 According to a new market ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast, ... at USD 12,212.9 million in 2013 and is estimated ... CAGR of 7.2% from 2014 to 2020. , Spectrometry ... light within specific electromagnetic spectrum to identify variety of ...
(Date:9/15/2014)... San Diego, CA (PRWEB) September 15, 2014 ... globe will gather this week, September 17-20, at ... annual International Plant-based Nutrition Healthcare Conference . ... educate gatekeepers of dietary-related advice—our physicians and healthcare ... efficacy of whole food, plant-based nutrition and its ...
Breaking Medicine News(10 mins):Health News:Avenidas Village Celebrates Anniversary 2Health News:Kids' Severe Respiratory Virus Confirmed in Northeast 2Health News:Kids' Severe Respiratory Virus Confirmed in Northeast 3Health News:Network measures predict neuropsychological outcome after brain injury 2Health News:Spectrometry Market Expected to Reach USD 19.6 Billion Globally in 2020: Transparency Market Research 2Health News:Spectrometry Market Expected to Reach USD 19.6 Billion Globally in 2020: Transparency Market Research 3Health News:Spectrometry Market Expected to Reach USD 19.6 Billion Globally in 2020: Transparency Market Research 4Health News:Spectrometry Market Expected to Reach USD 19.6 Billion Globally in 2020: Transparency Market Research 5Health News:San Diego Plays Host This Week to International Plant-based Nutrition Healthcare Conference Featuring Drs. Ornish, Esselstyn, Campbell and Other Leading Experts 2Health News:San Diego Plays Host This Week to International Plant-based Nutrition Healthcare Conference Featuring Drs. Ornish, Esselstyn, Campbell and Other Leading Experts 3
... Center have discovered the genetic factors that make some mosquitoes ... protein in the mosquitos immune system is the key to ... with a parasite that causes malaria, a biochemical reaction is ... of grabbing on to the parasites surface and targeting it ...
... a teenager Scot of severe asthma. ,Fifteen-year-old ... had to give up sports and physical education lessons at ... had read somewhere about the benefits of playing wind instruments ... one. ,Being a proud Glasgow-born Scot, David ...
... 18 months ago said Friday she felt reborn, but admitted ... of sadness and wonder. ,"I am back in the ... expressions which allow them to communicate. And I am alive again," ... of Le Monde. ,But the single mother, whose nose, ...
... constant headlines in the western media, the emerging Asian ... has suspended the sale of a drug used to treat ... week alone, a former department head at the State Food ... and it was announced that production licenses of five drug ...
... Actress Katie Holmes has landed a place in OK! ... ,The former 'Dawson's Creek' actress topped the 'beauty ... her new sporty cropped haircut, leaving singers Beyonce and ... the magazine created a list of 19 celebrities in ...
... confessed that she had sex with former boyfriend Justin Timberlake despite ... married. ,"I've only slept with one person my whole ... Justin, and I thought he was the one. But I was ... most painful thing I have ever experienced was that break-up," Spears ...
Cached Medicine News:Health News:Genetic Factors Behind Mosquitoes Resistance to Malaria Identified 2Health News:World's First Face Transplant Patient Feels She is Alive Again 2Health News:China Cracks the Whip Against Drug Manufacturers Who Fail Quality Norms 2
Acuvue Toric is an exceptionally comfortable soft contact lens made especially for people with astigmatism. The Acuvue Toric lens is designed to comfortably fit the unique shape of your eye....
C 2.3K with lightweight headband: the practical alternative for spectacle-wearers. Delivered in protective designer case....
Easyloupes are exceptional optics that you have come to expect from Oculus. Available in either 1.8x or 2.5x magnification and 40 cm working distance (15.75 inches), they have the well-known durabili...
... designed for computer operators who require ... placed at different heights and distanced ... Card is printed two sided- black ... and uses two type sizes to ...
Medicine Products: